Kornimate/medical-research-clean huggingface dataset:
smartphones aggravating anxiety symptoms

Conditions: Anxiety

Summary: the goal of this study is to assess if excessive use of smartphone apps of social media can impact a person's mental health. the study is aimed at improving the usage of smartphones which might help improve the mental health of patients. the goal is not to discourage the use of smartphones but instead to utilize smartphones in a way that they do not impact lives.


Eligibility criteria:
inclusion criteria: * for patients aged 18 years or older experiencing mild symptoms of anxiety or depression and who have a gad-7 score 5 and above. * patient should have smart phone and should be using facebook, instagram, twitter, tik tok, and pinterest social media apps. * patients should have email access. exclusion criteria: * any patient who uses a smartphone for tracking glucose for diabetes management, heart rate, or any chronic illness which is being managed through a smartphone app. * any patient who uses more than one personal smartphone * any patient who is a suicide risk as per phq-9 score, current recreational drug usage, or alcohol abuse. * any patient who has suicidal ideation as per phq-9 assessment before or during the study period will be excluded, (all patients will be monitored for suicidal ideation by phq-9 scoring method at day 1, week 6, and week 12, but it is the responsibility of the patient to inform the study team if they have developed any suicidal ideation throughout the study period). * patients with activated poa (power of attorney - healthcare), diagnosis of mental retardation or current disability due to any psychiatric disorder or severe depression with a high risk of suicide should be excluded. * any patient currently undergoing ect (electroconvulsive therapy) for severe depression. * any patient taking prescribed ssris/snris, with a change and not taking them continuously in last 30 days (not a new diagnosis of anxiety). if change they will be excluded.

Keywords: smartphones
intravenous enhancin[co-amoxiclav] versus postoperative enhancin in prevention of postadenotonsillectomy morbidity.

Conditions: Adenotonsillar Hypertrophy,Under 12 Years.

Summary: null hypothesis; the efficacy of enhancin\]co-amoxiclav given as a single intravenous dose at induction is not better than a five days oral course of the same given postoperatively in reducing postoperative morbidity after adenotonsillectomy.

adenotonsillectomy results in morbidity that is reduced by the use of antibiotics.this study had the sole objective of comparing two route of administration to see which has superior results.

Eligibility criteria:
inclusion criteria: * patients below 12year scheduled to undergo adenotonsillectomy whose parents or guardians give consent for recruitment into the study. exclusion criteria: * non consenting parents or guardians. antibiotic use in the week preceding surgery. patients with co mordities. known allergies to co-amoxiclav. patients who develop complication that warrant change of antibiotic.

Keywords: adenotonsillectomy.
a phase 1b study to investigate safety and tolerability of argx-119 in adult participants with dok7-congenital myasthenic syndromes (cms)

Conditions: Congenital Myasthenic Syndrome

Summary: the purpose of this study is to assess the safety and tolerability of argx-119 in adult participants with dok7- congenital myasthenic syndromes. the study will also assess how argx-119 is processed by the body (pharmacokinetics), how the immune system reacts to it (immunogenicity), and how it may improve the way patients feel and function. after the screening period, eligible participants will be randomized in a 4:1 ratio to receive intravenous infusions of argx-119 or placebo during the treatment period. participants will then enter the follow-up period. the full duration of the study is approximately 11 months.


Eligibility criteria:
inclusion criteria: * at least 18 years of age. * has genetically confirmed congenital myasthenic syndromes due to mutation of downstream of kinase 7 (dok7-cms). * participants taking oral beta agonists (eg, albuterol, salbutamol, ephedrine) must have been receiving the medication for more than 3 months and agree to remain on a same stable dosing regimen of the same medication until the end of the study. exclusion criteria: * diagnosis of cms due to mutation of any gene other than dok7. * known medical condition that would interfere with an accurate assessment of cms, confound the results of the study, or put the patient at undue risk, as assessed by the investigator. * history of malignancy, cancer, unless considered cured by adequate treatment with no evidence of recurrence for more than 5 years. adequately treated participants with the following cancers can be included at any time: basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, incidental histological findings of prostate cancer. * different study drug received in another clinical study within 12 weeks or 5 half-lives before screening. * current participation in another interventional clinical study or prior participation in any gene therapy or cell therapy study. * pregnant or lactating state or intention to become pregnant during the study. the complete list of exclusion criteria can be found in the protocol.
the effect of exercise on blood glucose levels in patients with type 1 diabetes: a comparison of 3 long-acting insulins

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in europe. the aim of this research is to assess the impact of three basal (long-acting) insulin treatments on blood glucose levels in people with type 1 diabetes when performing physical exercise.


Eligibility criteria:
inclusion criteria: * type 1 diabetes * current basal-bolus insulin therapy * hba1c \< 10% * bmi \< 32 kg/m2 exclusion criteria: * proliferative retinopathy / maculopathy * recurrent major hypoglycaemias * impaired hepatic or renal function * cardiac problems * uncontrolled hypertension
covid-19 - sars-cov-2 community contamination in children and adults - impact of variants (dyn3cea - nosocor phase 2)

Conditions: Infection Viral

Summary: unlike other respiratory viruses such as influenza and rsv where the child is the essential reservoir and central vector of intrafamilial contamination, the child is likely to be a small player in the transmission of cov2-corsa infection. this study aims to describe the age category of the first contact, within 14 days before the appearance of the first symptoms of the index case in order to describe the age categories of this first contaminant, globally, in the group of children and finally in the group of adults. this work is intended to provide food for discussion and to justify the distancing and containment measures imposed on children when their isolation has a deleterious impact that has now been established for some children.


Eligibility criteria:
inclusion criteria: * 1) children hospitalized in the pediatric department of the hospices civils de lyon with pcr positive for a variant of the historical sars-cov2, 2) adults hospitalized in the the hospices civils de lyon, for a covid-19 disease with documented infection by a variant of the sars-cov-2 and included in the noso-cor study with matching criteria described below. exclusion criteria: 1. any patient suspected of nosocomial infection. 2. any patient death during the covid-19 infection. 3. any adult patient without children living home. 4. opposition to participate.
anthropometry in gastroesophageal reflux disease and esophageal injury

Conditions: Gastroesophageal Reflux Disease (GERD)

Summary: is waist to hip ratio (whr), waist circumference (wc), (as markers of visceral adiposity) associated with an increase in acidic and non acidic reflux as well as systemic inflammation involving esophageal mucosa, thereby increasing esophageal injury and predisposing to subsequent development of barrett's esophagus (be)?

the investigators will study 100 adult subjects over the age of 18 from the esophageal motility lab who are undergoing clinically indicated 24 hour acidity or basicity (ph) impedance and/or ph studies off acid suppressing medication.. these subjects will not have a prior history of esophageal surgery, or diagnosis of be. the investigators will obtain consent for taking anthropometric measurements (waist and hip circumference), and the results of their study. only those subjects that successfully complete the 24 hour ph impedance studies will be included. subjects will also undergo clinically indicated endoscopy. the investigators will consent these subjects to obtain 4 biopsies (bx) from the gastroesophageal (ge) junction and 4 bx from 5 cm above the ge junction. these bio-specimens will be stored for assessment of tissue injury (pge2) and tissue immune-histochemistry of be precursors (cdx1 and cdx2) at a later date.

Eligibility criteria:
inclusion: * subjects over the age of 18 undergoing clinically indicated 24 hour ph impedance and/or ph studies. many will also undergo clinically indicated endoscopy, and consent for acquiring tissue samples for future biomarker staining tests will be obtained. * able to give informed consent exclusion: * subjects with a prior history of esophageal surgery, or diagnosis of be.

Keywords: gastroesophageal reflux disease gerd barrett's esophagus
serum metabolomics study of polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary syndrome (pcos) is a complex, heterogeneous disorder, which produces in 5-20% reproductive age women. in this study, a nontargeted metabolomics approach based on ultra high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry will be used to investigate serum metabolic characteristics of pcos. pcos women and healthy control will be divided into two distinct groups based on multivariate statistical analysis. the findings of this study will offer a new insight to understand the pathogenesis mechanism, and the discriminating metabolites may provide a prospect for pcos diagnosis.


Eligibility criteria:
inclusion criteria: * pcos diagnostic criteria: according to the diagnostic criteria revised by the european society of human reproduction and embryology and the american society for reproductive medicine at the rotterdam in 2003,4 pcos patients can be diagnosed if two of the three criteria are present after excluding congenial adrenal hyperplasia, cushing's syndrome, androgen secreting tumors, or other related disorders. the three criteria are (1) oligo- and/or anovulation; (2) clinical and/or biochemical signs of hyperandrogenism (clinical manifestations of hyperandrogenism include presence of acne, hirsutism, and androgenic alopecia); (3) polycystic ovaries by ultrasound examination: presence of 12 or more follicles in each ovary measuring 2-9 mm on diameter and/or ovarian volume\>10 ml. * age between 14 and 40 years * 2 years after menarche exclusion criteria: -
efficacy and safety study of neurostar tms therapy in patients with major depressive disorder with postpartum onset

Conditions: Depression, Postpartum

Summary: the purpose of this study is to evaluate the safety and effectiveness of acute neurostar tms therapy in women who have postpartum depression.

evaluate the antidepressant effectiveness of acute treatment with neurostar tms therapy in patients with mdd with postpartum onset. determine the safety of neurostar tms therapy by assessment of any medically significant, device-related adverse events during acute treatment. determine the safety of neurostar tms therapy by assessment of maternal and infant interactions on standardized bonding questionnaires.

Eligibility criteria:
inclusion criteria: * female outpatients, 18 to 50 years of age. * diagnosis of dsm-iv defined major depressive disorder, single or recurrent episode, with current episode duration of at least 2 weeks. * onset and duration of current illness within 6 months of live childbirth. * hamd17 total score of greater than or equal to 18 and a score on the edinburgh postnatal depression scale (epds) greater than or equal to 10. * patient cannot be on an antidepressant or other psychotropic medications during the study. * capable and willing to provide informed consent. * signed hipaa authorization. * able to adhere to the treatment schedule. exclusion criteria: * individuals diagnosed by the investigator with the following conditions (current unless otherwise stated): depression secondary to a general medical condition, or substance-induced seasonal pattern of depression as defined by dsm-iv;history of substance abuse or dependence within the past year(except nicotine and caffeine);any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features in this or previous episodes;bipolar disorder;eating disorder (current or within the past year);obsessive compulsive disorder (lifetime); or post-traumatic stress disorder (current or within the past year). * individuals with a clinically defined neurological disorder or insult including, but not limited to:any condition likely to be associated with increased intracranial pressure;space occupying brain lesion;history of cerebrovascular accident;transient ischemic attack within two years; cerebral aneurysm; dementia;parkinson's disease;huntington's chorea;multiple sclerosis. * history of treatment with vagus nerve stimulation. * history of failure to respond to an adequate course of ect treatment. * cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease. * intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed. * women of child-bearing potential not using a medically accepted form of contraception when engaging in sexual intercourse.

Keywords: postpartum depression, neurostar tms therapy, tms
first trimester placental assessment in the screening of preeclampsia and intrauterine growth restriction

Conditions: Preeclampsia; Intrauterine Growth Restriction

Summary: preeclampsia (pe) and intrauterine growth restriction (iugr) are clinical manifestations of placental insufficiency. these complications affect 5-15% of pregnancies, and are responsible for up to 20% of preterm births. women who develop pe during pregnancy also have an increased risk for cardiovascular events, both at short and long term. this justifies the need to improve diagnostic tools to identify patients at risk for these complications. pe and iugr are multifactorial entities. screening algorithms should thus include several parameters to achieve high detection rates. research has mainly focused in the analysis of biophysical and biochemical parameters, and the study of the placenta itself has not been included in current diagnostic strategies. investigators hypothesize that detection rates of preeclampsia and intrauterine growth restriction could be improved by the study of placental characteristics in the first trimester of pregnancy.


Eligibility criteria:
inclusion criteria: * pregnancies with fetuses with crl between 45 and 80mm * absence of chromosomal abnormalities * absence of congenital anomalies * absence of congenital infections exclusion criteria: * patient not accepting to participate in the study * multiple pregnancies * pregnancies without ultrasonographic confirmation of gestational age

Keywords: placental volume first-trimester screening ultrasound preeclampsia intrauterine growth restriction biochemical markers uterine artery doppler
does anxiety in children on the day of surgery impact compliance in the ophthalmology clinic?

Conditions: Anxiety; Strabismus; Compliance

Summary: the hypothesis is that pediatric patients with increased levels of anxiety on the day of surgery, in particular at point of anesthetic induction, will demonstrate decreased compliance with assessment in ophthalmology clinic postoperatively.

there are many studies demonstrating pediatric anxiety from a surgical experience leading to postoperative maladaptive behaviors such as nightmares, separation anxiety, eating problems, and increased fear of doctors. there is a significant amount of research looking at day of surgery anxiety and pain in children and possible modifiers. very little work has explored the effect of maladaptive behaviors with follow up physician visits. strabismus surgery is particularly important as children require early and regular follow up assessments after surgery for optimal outcome. these assessments are meticulous and require good patient cooperation in order to obtain useful information for the pediatric ophthalmologist. the study hypothesis is that pediatric patients with increased levels of anxiety on the day of surgery, in particular at point of anesthetic induction, will demonstrate decreased compliance with assessment in ophthalmology clinic postoperatively. the investigators expect this decrease in compliance will be evident based on changes seen on the ophthalmology clinic compliance scores generated pre and postoperatively. the proposed study will be a prospective cross sectional study. investigators will be measuring compliance in the ophthalmology clinic pre and postoperative and relating any changes in compliance with anxiety levels on the day of surgery.

Eligibility criteria:
inclusion criteria: * age 3 - 10 years old * asa i - iii * primary strabismus surgery one or both eyes exclusion criteria: * preexisting anxiety disorder * preexisting chronic pain or chronic analgesia use * neurobehavioural pathology limiting our ability to assess the patient eg: cerebral palsy, autism or developmental delay. * inability to adhere to study protocol * consult in anesthesiology clinic prior to surgery

Keywords: anesthesiology ophthalmology
the effect of kinesio® tex application on pain, functionality, sleep quality and work performance in drivers

Conditions: Neck Pain; Back Pain; Occupational Diseases

Summary: this study was planned to examine the effect of kinesio® tex application on pain, functionality, sleep quality and work performance in drivers experiencing neck-back pain.

50 active drivers will be included in the study. the drivers included in the study will be randomly divided into two groups as exercise group and taping group. the home exercise program will be visually explained to both groups and the exercises will be sent to the participants as video. kinesio® tex will also be applied to the banding group. evaluations will be made before treatment and after 6 weeks of treatment. within the scope of the evaluation, demographic information of the patients, work experience, daily working time, dominant hand, education information (university / high school), type of vehicle used, habit of leaning elbow on the left window, diseases and drugs used, smoking and alcohol use, given after mutual interview will be obtained by recording the answers. joint range of motion, manual muscle test, pain severity of the individuals participating in the study with the visual analog scale, neck functionality assessment with the neck disability indicator, back functionality assessment with the quebec back-low back pain disability scale, sleep quality assessment with the pittsburgh sleep quality index, work performance assessment to be assessed by the work role functioning questionnaire

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study having signed the voluntary consent form. * being between the ages of 18-65 * working in home health services for at least 2 years * reporting symptoms of localized pain and discomfort in the neck-back region lasting at least 1 week in the last 12 months exclusion criteria: * the participant's wish to terminate the study * receiving physical therapy for neck-back pain in the last 3 months * findings such as pins and needles, numbness and tingling in the upper extremity * having an allergy to taping * presence of a known specific disease that may cause chronic neck-back pain (nerve root compression, postoperative condition in the neck and shoulder regions, peripheral entrapment neuropathy, cervical spine anomaly, severe neck trauma such as whiplash, malignancy, migraine). * alcohol and drug addiction * psychological conditions that may cause physical burden and recent major operations * presence of a skin disease that will affect the neck and back area

Keywords: taping kinesio® tex functionality work performance
first-in-man early feasibility study for transcatheter hocm septal ablation

Conditions: Hypertrophic Obstructive Cardiomyopathy

Summary: transcatheter intra-septal rf ablation system (tira catheter with its supplemental devices) to treat hypertrophic obstructive cardiomyopathy.

the objective of this multi-center, open label, single arm, investigator initiated exploratory pilot study is to evaluation of safety and efficacy of transcatheter intra-septal rf ablation system (tira catheter with its supplemental devices), in treating hypertrophic obstructive cardiomyopathy(hocm).

Eligibility criteria:
inclusion criteria: * males and females aged 20 years or older * nyha(new york heart association) class ⅱ to ⅳ in spite of optimal medical treatment. (for optimal medical treatment, β-blocker or diuretic such as calcium antagonists should be given for at least 3 months.) * patients with left ventricular effusion gradient (lvot) greater than (1) 30 mmhg at rest or (2) at least 50 mmhg at physiological exercise/dobutamine administration/balsalva manuver. (the pressure difference due to the left ventricle drain must be the proximal mitral valve-septal contact by the systolic motion of mitral valve (sam).) * patients who voluntarily decide to participate in this clinical trial and provide written informed consent. * patients who are able to understand and follow instructions and participate for the entire duration of the clinical trial. exclusion criteria: * target area wall thickness ≤15mm * lv ejection fraction ≤40% * subjects who have unsuitable septal vein and coronary sinus anatomy by cardiac ct or venogram * conduction disturbance; lbbb or rbbb * advanced av block without permanent pacemaker * subjects who have experience in performing vascular stent procedures (pci) or cabg on coronary arteries close to the coronary sinus within 3 months. * severe pulmonary htn ≥70mmhg * patients who have cardiogenic shock and those who have an expected life expectancy of 12 months or less. * patients with other valve diseases (companion disease) that require surgical treatment (in this case, systolic motion of the mitral valve (sam) caused by systolic myocardia is not considered a companion disease). * patients who are pregnant, or lactating, or plan pregnacy during the clinical trials * patients who are participated in other clinical trials within 1 month of enrollment * patients who are deemed not to be eligible in this study by physician's discretion

Keywords: transcatheter rf ablation intraseptal ablation hocm taupnu
a dosing study of intravitreal bevacizumab for retinopathy of prematurity

Conditions: Retinopathy of Prematurity

Summary: the aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab is effective in treatment of type 1 rop as the standard 0.625 mg dose., regarding : serum systemic vegf levels. retinal vascularization.


Eligibility criteria:
inclusion criteria: infants with type 1 rop according to etrop study which is defined as: * zone i rop with plus disease * zone i, stage 3 rop without plus disease * zone ii, stage 2 or 3 rop with plus disease exclusion criteria: * eyes with previous intravitreal injection * eyes with previous laser therapy * eyes with any other intraocular pathology other than rop (congenital cataract, congenital glaucoma, any retinal pathology other than rop)